Abstract | BACKGROUND: DATA SOURCES AND STUDY SELECTION: DATA SYNTHESIS: CONCLUSIONS: Although SSRIs may demonstrate therapeutic benefit in autism spectrum disorders, methodological weaknesses of many of the clinical trials suggest the need for additional randomized controlled trials. Furthermore, given the increased awareness of the dangers associated with SSRI-induced activation and agitation, the presence of these side effects in the autistic population warrants closer attention to dosage, titration, and subject selection issues.
|
Authors | Alexander Kolevzon, Karen A Mathewson, Eric Hollander |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 67
Issue 3
Pg. 407-14
(Mar 2006)
ISSN: 0160-6689 [Print] United States |
PMID | 16649827
(Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Serotonin Uptake Inhibitors
|
Topics |
- Adolescent
- Adult
- Autistic Disorder
(drug therapy, psychology)
- Child
- Child, Preschool
- Clinical Trials as Topic
- Double-Blind Method
- Female
- Humans
- Male
- Medical Records
- Randomized Controlled Trials as Topic
- Research Design
(standards)
- Retrospective Studies
- Selective Serotonin Reuptake Inhibitors
(adverse effects, therapeutic use)
- Treatment Outcome
|